Joaquín Quiralte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Joaquín Quiralte has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Mayte Villalba
Department of Biochemistry and Molecular Biology, Universidad Complutense de Madrid, Madrid, Spain
10 shared publications - Blanca Cárdaba
Immunology Department, IIS-Fundación Jiménez Díaz-UAM, 28040 Madrid, Spain
5 shared publications - Carlos Blanco
Department of Allergy Hospital Universitario de La Princesa, IIS‐Princesa Madrid Spain
4 shared publications Fernando Florido
Allergy Department, San Cecilio University Hospital, Granada, Spain
4 shared publications- Oscar Palomares
Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain
4 shared publications R. Rodríguez
Departamento de Bioquímica y Biología Molecular, Facultad de Química, Universidad Complutense de Madrid, Madrid, Spain
4 shared publications
Latest Publications
- Open Access
- 4 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 15942
Therapeutic potential of peptides from Ole e 1 in olive-pollen allergy
Olive-pollen allergy is one of the leading causes of respiratory allergy in Mediterranean countries and some areas of North America. Currently, allergen-specific immunotherapy is the only etiophatogenic treatment. However, this approach is not fully optimal, safe, or effective. Thus, efforts continue in the search for novel immunotherapy strategies, being one of the most promising the use of peptides derived from major allergens. This work tries to determine the therapeutic potential and safety of 5 dodecapeptides derived from the main allergen of olive-pollen allergy, Ole e 1. The immunomodulatory capacity of these peptides was studied using peripheral blood mononuclear cells (PBMCs) obtained from 19 olive-pollen-allergic patients and 10 healthy controls. We determined the capacity of these peptides to inhibit the proliferative response toward olive-pollen allergenic extract and to induce the regulatory cytokines, IL-10 and IL-35. To test the safety and absence of allergenicity of the peptides, the basophil activation was analyzed by flow-cytometry, using peripheral blood. The results showed that two of five peptides inhibited near to 30% the proliferative response against the total olive-pollen allergenic extract in olive-pollen-allergic patients. Inhibition increased to nearly 35% when the 5 peptides were used in combination. In both cases, a statistically significant induction of IL-10 and IL-35 secretion was observed in the supernatants of allergic patients PBMCs cultures. None of the 5 peptides induced basophil activation and cross-link inflammatory cell-bound IgE. In conclusion, these results open up new possibilities in the treatment of olive-pollen allergy, which could solve some of the problems facing current therapy approaches.
- 4 November 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 15942
Open AccessTherapeutic potential of peptides from Ole e 1 in olive-pollen allergy
Olive-pollen allergy is one of the leading causes of respiratory allergy in Mediterranean countries and some areas of North America. Currently, allergen-specific immunotherapy is the only etiophatogenic treatment. However, this approach is not fully optimal, safe, or effective. Thus, efforts continue in the search for novel immunotherapy strategies, being one of the most promising the use of peptides derived from major allergens. This work tries to determine the therapeutic potential and safety of 5 dodecapeptides derived from the main allergen of olive-pollen allergy, Ole e 1. The immunomodulatory capacity of these peptides was studied using peripheral blood mononuclear cells (PBMCs) obtained from 19 olive-pollen-allergic patients and 10 healthy controls. We determined the capacity of these peptides to inhibit the proliferative response toward olive-pollen allergenic extract and to induce the regulatory cytokines, IL-10 and IL-35. To test the safety and absence of allergenicity of the peptides, the basophil activation was analyzed by flow-cytometry, using peripheral blood. The results showed that two of five peptides inhibited near to 30% the proliferative response against the total olive-pollen allergenic extract in olive-pollen-allergic patients. Inhibition increased to nearly 35% when the 5 peptides were used in combination. In both cases, a statistically significant induction of IL-10 and IL-35 secretion was observed in the supernatants of allergic patients PBMCs cultures. None of the 5 peptides induced basophil activation and cross-link inflammatory cell-bound IgE. In conclusion, these results open up new possibilities in the treatment of olive-pollen allergy, which could solve some of the problems facing current therapy approaches.
- Open Access
- 24 October 2018
- Published by Universidad Internacional de Andalucia
- p. 72-87
Anafilaxia. Manejo práctico de autoinyectores de adrenalina
- 24 October 2018
- Published by Universidad Internacional de Andalucia
- p. 72-87
Open AccessAnafilaxia. Manejo práctico de autoinyectores de adrenalina
- Open Access
- 26 October 2017
- Published by Universidad Internacional de Andalucia
- p. 8-17
Los 5 pasos para abordar el asma polínico
- 26 October 2017
- Published by Universidad Internacional de Andalucia
- p. 8-17
Open AccessLos 5 pasos para abordar el asma polínico
- Open Access
- 1 February 2017
- Published by Elsevier in Data in Brief
- Vol. 10, 505-510
Data set on a study of gene expression in peripheral samples to identify biomarkers of severity of allergic and nonallergic asthma
- 1 February 2017
- Published by Elsevier in Data in Brief
- Vol. 10, 505-510
Open AccessData set on a study of gene expression in peripheral samples to identify biomarkers of severity of allergic and nonallergic asthma
- 1 February 2017
- Published by Elsevier in Molecular Immunology
- Vol. 82, 34-45
Biomarkers associated with disease severity in allergic and nonallergic asthma
- 1 February 2017
- Published by Elsevier in Molecular Immunology
- Vol. 82, 34-45
Biomarkers associated with disease severity in allergic and nonallergic asthma
- 1 October 2010
- Published by Springer Nature in PharmacoEconomics Spanish Research Articles
- Vol. 7 (4) , 163-175
Análisis coste-efectividad de budesonida/formoterol en el tratamiento de mantenimiento y a demanda (Symbicort SMART®) frente a salmeterol/fluticasona más terbutalina, en el tratamiento del asma persistente en España
- 1 October 2010
- Published by Springer Nature in PharmacoEconomics Spanish Research Articles
- Vol. 7 (4) , 163-175
Análisis coste-efectividad de budesonida/formoterol en el tratamiento de mantenimiento y a demanda (Symbicort SMART®) frente a salmeterol/fluticasona más terbutalina, en el tratamiento del asma persistente en España
- 1 September 2010
- Published by Bentham Science Publishers Ltd. in Inflammation & Allergy - Drug Targets
- Vol. 9 (4) , 257-262
Defining the role of food allergy in a population of adult patients with eosinophilic esophagitis.
Abstract: The aim of this study was to establish the clinical types of food reactions and the food sensitization profile in an adult cohort of patients with Eosinophilic esophagitis (EoE). We have prospectively analyzed the food allergen sensitization profile using skin prick test (SPT) and atopy patch test (APT) to 22 plant and animal-derived foods in 19 adult patients with biopsy-proven EoE. For each patient the following data was collected: age, sex, atopic disease status, and clinical characteristics of the EoE. A total of 123 food sensitizations were detected by SPT and 45 food sensitizations by patch testing in 18 patients (94.8%). Thirty-five double- positive (SPT+, APT+) responses against the same food were detected in 15 patients (78.9%). We have also identified 11 clinical episodes clearly suggestive of oral allergy syndrome, urticaria and/or anaphylaxis after intake of some specific foods. All cases showed positive SPT to the offending food (Type 1 food reactors). 68 clinically apparent episodes of EoE related with specific foods were detected in our patients. In 40 instances (58.8%) the foods involved in developing EoE symptoms showed a positive SPT and/or APT results (Type 2). 155 food sensitizations were identified in 18 patients (94.7%) using SPT and/or APT neither related with clinically apparent episodes of EoE nor with clinical episodes suggestive of oral allergy syndrome, urticaria and/or anaphylaxis after food intake (Type 3). In conclusion, the patients with EoE can be allocated into 3 different groups of food reactors, with well-defined clinical and biological characteristics.
- 1 September 2010
- Published by Bentham Science Publishers Ltd. in Inflammation & Allergy - Drug Targets
- Vol. 9 (4) , 257-262
Defining the role of food allergy in a population of adult patients with eosinophilic esophagitis.
Abstract: The aim of this study was to establish the clinical types of food reactions and the food sensitization profile in an adult cohort of patients with Eosinophilic esophagitis (EoE). We have prospectively analyzed the food allergen sensitization profile using skin prick test (SPT) and atopy patch test (APT) to 22 plant and animal-derived foods in 19 adult patients with biopsy-proven EoE. For each patient the following data was collected: age, sex, atopic disease status, and clinical characteristics of the EoE. A total of 123 food sensitizations were detected by SPT and 45 food sensitizations by patch testing in 18 patients (94.8%). Thirty-five double- positive (SPT+, APT+) responses against the same food were detected in 15 patients (78.9%). We have also identified 11 clinical episodes clearly suggestive of oral allergy syndrome, urticaria and/or anaphylaxis after intake of some specific foods. All cases showed positive SPT to the offending food (Type 1 food reactors). 68 clinically apparent episodes of EoE related with specific foods were detected in our patients. In 40 instances (58.8%) the foods involved in developing EoE symptoms showed a positive SPT and/or APT results (Type 2). 155 food sensitizations were identified in 18 patients (94.7%) using SPT and/or APT neither related with clinically apparent episodes of EoE nor with clinical episodes suggestive of oral allergy syndrome, urticaria and/or anaphylaxis after food intake (Type 3). In conclusion, the patients with EoE can be allocated into 3 different groups of food reactors, with well-defined clinical and biological characteristics.
- Open Access
- 11 June 2010
- Published by Wiley in The FEBS Journal
- Vol. 277 (13) , 2729-2739
Pectin methylesterases of pollen tissue, a major allergen in olive tree
Olive tree (Olea europaea) pollen is a main cause of allergy in Mediterranean areas and North America. A novel allergen, Ole e 11, has been detected by proteomic techniques. Protein bands binding IgE from allergic sera were excised from a 2D electrophoresis gel and analysed by Edman degradation and MALDI‐TOF MS. Four peptides were sequenced and used for designing primers to clone the cDNA codifying the protein. Ole e 11 consists of a 342 amino acid length polypeptide with a molecular mass of 37.4 kDa and a pI of 7.8. The allergen was identified as a pectin methylesterase and showed low identity with other members of this family from foods such as those from carrot (23%), orange (25%) and tomato (24%), and higher identity with those from Arabidopsis thaliana (57%) and Salsola kali (54%) pollen. The protein was overproduced in Pichia pastoris, purified, and characterized as an active enzyme. CD analysis rendered 3%α‐helix, 50%β‐sheet and 27%β‐turns for its secondary structure, which is in agreement with other pectin methylesterase structures. The recombinant protein was demonstrated to be immunologically equivalent to the natural form by immunoblotting, indirect ELISA and inhibition experiments, using polyclonal antiserum and sera from olive pollen allergic patients. The prevalence fluctuated between 55.9% and 75.6% in three different allergic populations. The availability of this new olive pollen allergen could improve the component‐resolved diagnosis. Its allergenic relevance is stepped up by the biotechnological use of these enzymes to improve organoleptic properties in processing foods and further confirms the need to include it in an accurate diagnosis.
- 11 June 2010
- Published by Wiley in The FEBS Journal
- Vol. 277 (13) , 2729-2739
Open AccessPectin methylesterases of pollen tissue, a major allergen in olive tree
Olive tree (Olea europaea) pollen is a main cause of allergy in Mediterranean areas and North America. A novel allergen, Ole e 11, has been detected by proteomic techniques. Protein bands binding IgE from allergic sera were excised from a 2D electrophoresis gel and analysed by Edman degradation and MALDI‐TOF MS. Four peptides were sequenced and used for designing primers to clone the cDNA codifying the protein. Ole e 11 consists of a 342 amino acid length polypeptide with a molecular mass of 37.4 kDa and a pI of 7.8. The allergen was identified as a pectin methylesterase and showed low identity with other members of this family from foods such as those from carrot (23%), orange (25%) and tomato (24%), and higher identity with those from Arabidopsis thaliana (57%) and Salsola kali (54%) pollen. The protein was overproduced in Pichia pastoris, purified, and characterized as an active enzyme. CD analysis rendered 3%α‐helix, 50%β‐sheet and 27%β‐turns for its secondary structure, which is in agreement with other pectin methylesterase structures. The recombinant protein was demonstrated to be immunologically equivalent to the natural form by immunoblotting, indirect ELISA and inhibition experiments, using polyclonal antiserum and sera from olive pollen allergic patients. The prevalence fluctuated between 55.9% and 75.6% in three different allergic populations. The availability of this new olive pollen allergen could improve the component‐resolved diagnosis. Its allergenic relevance is stepped up by the biotechnological use of these enzymes to improve organoleptic properties in processing foods and further confirms the need to include it in an accurate diagnosis.
- 26 November 2009
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (22) , 2197-2198
COX-2 Inhibitors in Patients with Sensitivity to Nonselective NSAIDs
Controlled oral challenge is the only definitive way to detect sensitivity to nonsteroidal antiinflammatory drugs (NSAIDs) in patients with adverse reactions to these agents.1 Patients who have adverse reactions to nonselective NSAIDs have very limited analgesic and antiinflammatory therapeutic options, but several studies have shown that highly selective cyclooxygenase-2 (COX-2) inhibitors can be safely used.2-4 However, in a small percentage of cases, adverse reactions (respiratory or cutaneous) have been observed during challenge with a COX-2 inhibitor.5 When these occur, the next step to be taken is not clear. Can we use another highly selective COX-2 inhibitor as a safe alternative? We present two patients with skin reactions to highly selective COX-2 inhibitors (confirmed by oral challenge) who had no adverse reactions to another COX-2 inhibitor.
- 26 November 2009
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (22) , 2197-2198
COX-2 Inhibitors in Patients with Sensitivity to Nonselective NSAIDs
Controlled oral challenge is the only definitive way to detect sensitivity to nonsteroidal antiinflammatory drugs (NSAIDs) in patients with adverse reactions to these agents.1 Patients who have adverse reactions to nonselective NSAIDs have very limited analgesic and antiinflammatory therapeutic options, but several studies have shown that highly selective cyclooxygenase-2 (COX-2) inhibitors can be safely used.2-4 However, in a small percentage of cases, adverse reactions (respiratory or cutaneous) have been observed during challenge with a COX-2 inhibitor.5 When these occur, the next step to be taken is not clear. Can we use another highly selective COX-2 inhibitor as a safe alternative? We present two patients with skin reactions to highly selective COX-2 inhibitors (confirmed by oral challenge) who had no adverse reactions to another COX-2 inhibitor.
- 1 September 2009
- Published by Wiley in Contact Dermatitis
- Vol. 61 (3) , 176
Occupational contact urticaria caused by donepezil
- 1 September 2009
- Published by Wiley in Contact Dermatitis
- Vol. 61 (3) , 176
Occupational contact urticaria caused by donepezil